Search Results - "Cohen, J.A."

Central vein sign: A diagnostic biomarker in multiple sclerosis (CAVS-MS) study protocol for a prospective multicenter trial by Ontaneda, D., Sati, P., Raza, P., Kilbane, M., Gombos, E., Alvarez, E., Azevedo, C., Calabresi, P., Cohen, J.A., Freeman, L., Henry, R.G., Longbrake, E.E., Mitra, N., Illenberger, N., Schindler, M., Moreno-Dominguez, D., Ramos, M., Mowry, E., Oh, J., Rodrigues, P., Chahin, S., Kaisey, M., Waubant, E., Cutter, G., Shinohara, R., Reich, D.S., Solomon, A., Sicotte, N.L.

“…•Approximately one in five patients with MS do not have the disease.•The central vein differentiates multiple sclerosis from other white matter lesions.•The…”
Get full text

91. Adult-onset rippling muscle disease by Vertrees, S.M, Cohen, J.A

Get full text

Evaluation of distal symmetric polyneuropathy: The role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review) by England, J.D., Gronseth, G.S., Franklin, G., Carter, G.T., Kinsella, L.J., Cohen, J.A., Asbury, A.K., Szigeti, K., Lupski, J.R., Latov, N., Lewis, R.A., Low, P.A., Fisher, M.A., Herrmann, D., Howard, J.F., Lauria, G., Miller, R.G., Polydefkis, M., Sumner, A.J.

“…Distal symmetric polyneuropathy (DSP) is the most common variety of neuropathy. Since the evaluation of this disorder is not standardized, the available…”
Get full text

Investigating the role of polyunsaturated fatty acids in bone development using animal models by Lau, Beatrice Y Y, Cohen, Daniel J A, Ward, Wendy E, Ma, David W L

“…Incorporating n-3 polyunsaturated fatty acids (PUFA) in the diet may promote the development of a healthy skeleton and thereby reduce the risk of developing…”
Get full text

Evaluation of distal symmetric polyneuropathy: The role of laboratory and genetic testing (an evidence-based review) by England, J.D., Gronseth, G.S., Franklin, G., Carter, G.T., Kinsella, L.J., Cohen, J.A., Asbury, A.K., Szigeti, K., Lupski, J.R., Latov, N., Lewis, R.A., Low, P.A., Fisher, M.A., Herrmann, D., Howard, J.F., Lauria, G., Miller, R.G., Polydefkis, M., Sumner, A.J.

“…Distal symmetric polyneuropathy (DSP) is the most common variety of neuropathy. Since the evaluation of this disorder is not standardized, the available…”
Get full text

Alemtuzumab improves visual outcomes in treatment-naïve patients with relapsing–/INS;remitting multiple sclerosis (RRMS): Analysis from the phase 3 CARE-MS I study by Balcer, L.J, Arnold, D.L, Cohen, J.A, Coles, A.J, Confavreux, C, Fox, E.J, Hartung, H.-P, Havrdova, E, Selmaj, K.W, Weiner, H.L, Brinar, V, Giovannoni, G, Stojanovic, M, Cinar, A, Margolin, D.H, Panzara, M, Compston, D.A.S

Get full text

Adverse event profile of alemtuzumab over time in treatment-naïve patients with early, active relapsing–/INS;remitting multiple sclerosis (RRMS; CARE-MS I study) by Lycke, J, Arnold, D.L, Cohen, J.A, Coles, A.J, Confavreux, C, Fox, E.J, Hartung, H.-P, Havrdova, E, Selmaj, K.W, Weiner, H.L, Brinar, V, Giovannoni, G, Stojanovic, M, Lake, S.L, Margolin, D.H, Panzara, M, Compston, D.A.S

Get full text

Alemtuzumab treatment has no adverse impact on sperm quality, quantity, or motility: A CARE-MS substudy by Margolin, D.H, Rizzo, M.A, Smith, G, Arnold, D.L, Cohen, J.A, Coles, A.J, Confavreux, C, Fox, E.J, Hartung, H.-P, Havrdova, E, Selmaj, K.W, Weiner, H.L, Brinar, V, Giovannoni, G, Miller, T.A, Stojanovic, M, Twyman, C.L, Lake, S.L, Panzara, M, Compston, D.A.S

Get full text

Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS) by Khatri, B.O, Pelletier, J, Kappos, L, Hartung, H.-P, Comi, G, Barkhof, F, von Rosenstiel, P, Meng, X, Grinspan, A, Hashmonay, R, Cohen, J.A

“…Abstract Background Fingolimod demonstrated superior efficacy compared with interferon β-1a intramuscular in relapsing multiple sclerosis. The impact of…”
Get full text

Intrarater and interrater reliability of the MS functional composite outcome measure by COHEN, J. A, FISCHER, J. S, BOLIBRUSH, D. M, JAK, A. J, KNIKER, J. E, MERTZ, L. A, SKARAMAGAS, T. T, CUTTER, G. R

“…To assess practice effects, and intrarater and interrater reliability of the MS functional composite (MSFC) outcome measure. To address the poor reliability…”
Get full text

Practice Parameter: The Evaluation of Distal Symmetric Polyneuropathy: The Role of Autonomic Testing, Nerve Biopsy, and Skin Biopsy (An Evidence-Based Review) by England, J.D., MD, Gronseth, G.S., MD, Franklin, G., MD, Carter, G.T., MD, Kinsella, L.J., MD, Cohen, J.A., MD, Asbury, A.K., MD, Szigeti, K., MD, PhD, Lupski, J.R., MD, PhD, Latov, N., MD, Lewis, R.A., MD, Low, P.A., MD, Fisher, M.A., MD, Herrmann, D, Howard, J.F., MD, Lauria, G, Miller, R.G., MD, Polydefkis, M, Sumner, A.J., MD

“…Background Distal symmetric polyneuropathy (DSP) is the most common variety of neuropathy. Since the evaluation of this disorder is not standardized, the…”
Get full text

Surgical trial investigating nocturnal gastroesophageal reflux and sleep (STINGERS) by COHEN, J. A, ARAIN, A, HARRIS, P. A, BYRNE, D. W, HOLZMAN, M. D, SHARP, K. W, RICHARDS, W. O

“…Nocturnal reflux is important in the pathogenesis of esophagitis. The relationship between reflux and sleep is poorly understood, although data support both…”
Get full text

Knowledge of radiation legislation and guidelines amongst foundation doctors is inadequate for safe practice in the current era of radiology by Cohen, J.A.

“…It is important for safe practice in radiology that junior doctors are aware of the guidelines and legislation surrounding ionising radiation; however, it has…”
Get full text

Practice Parameter: The Evaluation of Distal Symmetric Polyneuropathy: The Role ofLaboratory and Genetic Testing (An Evidence-Based Review) by England, J.D., MD, Gronseth, G.S., MD, Franklin, G., MD, Carter, G.T., MD, Kinsella, L.J., MD, Cohen, J.A., MD, Asbury, A.K., MD, Szigeti, K., MD, PhD, Lupski, J.R., MD, PhD, Latov, N., MD, Lewis, R.A., MD, Low, P.A., MD, Fisher, M.A., MD, Herrmann, D.N, Howard, J.F., MD, Lauria, G, Miller, R.G., MD, Polydefkis, M, Sumner, A.J., MD

“…Background Distal symmetric polyneuropathy (DSP) is the most common variety of neuropathy. Since the evaluation of this disorder is not standardized, the…”
Get full text

655 Cutaneous nociceptors trigger protective type-17 immunity through a nerve reflex arc by Cohen, J.A., Edwards, T.N., Liu, A., Hirai, T., Ritter-Jones, M., Wu, J., Li, Y., Ho, J., Davis, B., Albers, K., Kaplan, D.H.

Get full text

Treating sexually abused children: 1 year follow-up of a randomized controlled trial by Cohen, Judith A., Mannarino, Anthony P., Knudsen, Kraig

“…To measure the durability of improvement in response to two alternative treatments for sexually abused children. Eighty-two sexually abused children ages 8–15…”
Get full text

Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study by Goodman, A.D., Cohen, J.A., Cross, A., Vollmer, T., Rizzo, M., Cohen, R., Marinucci, L., Blight, A.R.

“…Objective To determine the safety of sustained-release 4-aminopyridine in subjects with mutiple sclerosis (MS) and to examine dose-related efficacy up to 40 mg…”
Get full text

P111 - “NO ENERGY, ZIP”: A MIXED METHODS COMPARISON OF FUNCTIONAL DECLINE DURING IMMUNOTHERAPY, TARGETED THERAPY, AND/OR CHEMOTHERAPY IN OLDER ADULTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) by Wong, M.L., Smith, A.K., Miaskowski, C., Musinipally, V., Cohen, H.J., Lam, V., Mazor, M., Ursem, C.J., Loh, K., Cohen, J.A., Shumay, D., Levin, A.O., Dixit, N., Grandi, J., Walter, L.C.

Get full text

“NO ENERGY, ZIP”: A MIXED METHODS COMPARISON OF FUNCTIONAL DECLINE DURING IMMUNOTHERAPY, TARGETED THERAPY, AND/OR CHEMOTHERAPY IN OLDER ADULTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) by Wong, M.L., Smith, A.K., Miaskowski, C., Musinipally, V., Cohen, H.J., Lam, V., Mazor, M., Ursem, C.J., Loh, K., Cohen, J.A., Shumay, D., Levin, A.O., Dixit, N., Grandi, J., Walter, L.C.

Get full text

Glatiramer acetate (copaxone) treatment in relapsing-remitting MS : Quantitative MR assessment by GE, Y, GROSSMAN, R. I, UDUPA, J. K, FULTON, J, CONSTANTINESCU, C. S, GONZALES-SCARANO, F, BABB, J. S, MANNON, L. J, KOLSON, D. L, COHEN, J. A

“…To evaluate the efficacy of glatiramer acetate (GA, Copaxone; Teva Pharmaceutical Industries, Ltd., Petah Tiqva, Israel) by MRI-based measures in patients with…”
Get full text